Reuters logo
BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests
December 4, 2017 / 6:13 AM / 7 days ago

BRIEF-Biocartis And Amgen Sign Companion Diagnostic Agreement For Idylla(Tm) RAS Biomarker Tests

Dec 4 (Reuters) - BIOCARTIS GROUP NV:

* BIOCARTIS AND AMGEN SIGN COMPANION DIAGNOSTIC AGREEMENT FOR IDYLLA(TM) RAS BIOMARKER TESTS

* BIOCARTIS -WILL PURSUE A PREMARKET APPROVAL FOR IDYLLA KRAS MUTATION TEST AND IDYLLA NRAS-BRAF MUTATION TEST WITH FDA​

* ‍AMGEN WILL PROVIDE FINANCIAL AND OPERATIONAL SUPPORT TO BIOCARTIS FOR PMA PROCESS​

* ‍AIM OF AGREEMENT IS TO REGISTER IDYLLA RAS BIOMARKER TESTS WITH US FDA AS COMPANION DIAGNOSTIC TEST FOR AMGEN‘S DRUG VECTIBIX(PANITUMUMAB) ​ Source text for Eikon: Further company coverage:, (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below